Purchase Order HT001419P0020
Award Date 11/20/18
Potential Completion Date 1/31/22
Potential Value $296K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20889, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $214,560.00, is for the delivery of INT2540B DROP SHIPMENT FOR PLATELET PROCESSING. This contract has no set-aside designation. Cerus Corporation is the prime contractor and there are no major subcontractors identified. The contract supports medical...
- The Defense Health Agency awarded Cerus Corporation, a biomedical products company, a firm-fixed-price purchase order contract worth $190,080.00 for the supply of INTERCEPT Platelet Processing Sets and INTERCEPT Platelet Processing Sets with Dual Storage Containers. The contract is a sole-source award due to the proprietary nature of Cerus Corporation's INTERCEPT Blood System technology, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components. This pathogen...
- This is a firm fixed-price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract, valued at $146,200.00, is for the procurement of INTERCEPT Blood System processing sets for dual storage. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components such as platelets and plasma, enhancing blood safety. Cerus has a history of supplying its...
- The Defense Health Agency awarded a $199,584 firm fixed-price purchase order to Cerus Corporation on January 5, 2024, for the procurement of Intercept Platelet Sets (PN INT2140B). The contract, which extends through September 30, 2028, will be performed at Cerus Corporation's facility in Concord, California. This award represents a continuation of the established relationship between the Defense Health Agency and Cerus Corporation for blood safety technologies, with no set-aside designation...
- This federal contract award, valued at $127,680.00, was issued by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the provision of INTERCEPT Platelet Processing Sets, which use Cerus' proprietary INTERCEPT Blood System to inactivate pathogens in blood components. The INTERCEPT system employs riboflavin and ultraviolet light to reduce the risk of transfusion-transmitted infections. This contract does...
- The Defense Health Agency (DOD) awarded a $367,504.80 firm fixed price purchase order to Cerus Corporation to provide INTERCEPT Platelet Processing and Service Maintenance for the Walter Reed National Military Center in Bethesda, Maryland from January 13, 2022 through January 31, 2027. Cerus Corporation will supply its INTERCEPT Blood System for platelets, which utilizes ultraviolet light and riboflavin to inactivate pathogens in platelet components during the collection and storage process,...
- This federal contract award is for the supply of INTERCEPT Platelet Small Volume Sets by Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $104,256.00, was awarded by the Defense Health Agency, a defense agency within the Department of Defense. The contract is a Firm Fixed Price Purchase Order with a period of performance through September 3, 2024. Cerus Corporation has a history of providing its...
- The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
- The Defense Health Agency awarded a $232,128 firm fixed-price purchase order to Cerus Corporation on October 1, 2024, for INTERCEPT Platelet Processing Kits to support the Naval Base San Diego Laboratory. The contract extends through September 30, 2028, and carries no set-aside designation. Cerus Corporation, headquartered in Concord, California, is a biomedical products manufacturer specializing in blood safety technologies and the INTERCEPT Blood System, a proprietary pathogen reduction...
- This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $14,924.64, is for the provision of INTERCEPT Blood System equipment, illuminator maintenance services, and specialized pathogen reduction technology products. The contract has a performance period ending on June 7, 2025. Cerus...